摘要
目的:对比阿立哌唑与奎硫平治疗首发精神分裂症的疗效和安全性。方法:分别以阿立哌唑与奎硫平治疗首发精神分裂症各60例,采用阳性症状和阴性症状量表(PANSS)、副反应量表(TESS),在治疗前及治疗后第1、2、4、6、8周未分别评定疗效及不良反应。结果:阿立哌唑有效率93.30%,显效率81.7%。奎硫平有效率96.7%,显效率83.3%,两组治疗后与治疗前PANSS评分比较差异有显著性,阿立哌唑不良反应少于奎硫平。结论:阿立哌唑治疗精神分裂症疗效较好,不良反应较奎硫平轻微,病人服药依从性良好。
Objective:To compare the efficacy and safety between aripiprazole and quetiapine. Methods:sixty schizophrenic patients were treeted with aripirazole and another sixty patients treated with quetiapine, the efficacy was measured with the positive and negative symptoms scale (PANSS) Results: while the side effects were determined by efficacy rate of aripiprazole was 93.3% ,in which 81.7%. were improved markedly ,The efficacy rate of quetiapine was 96.7% ,in which 83.3% were improved merkedly, the PANSS scores in both groups decreased significantly after treatment, aripirazole has less side effects than quetiaine. Conclusions: airpiprazole is of good efficacy, high safety and less side effects in treating schizophrenia, and patients and biter compliance.
出处
《中国民康医学》
2006年第17期759-760,共2页
Medical Journal of Chinese People’s Health